LSC Abstract – A functional variant of secretory leukocyte protease inhibitor (SLPI) with improved anti-inflammatory activity against pulmonary infection Source: International Congress 2015 – Immunomodulation: basic science and clinical aspects Year: 2015
Neuroendocrine differentiation in non-small cell lung cancer. A biochemical, immunohistological and ultrastructural evaluation of Chromogranin A Source: Eur Respir J 2006; 28: Suppl. 50, 783s Year: 2006
Clinical significance of MMP-9 and their tissue inhibitor TIMP-2 in lung adenocarcinomas ongoing study Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010
A functional variant of secretory leukocyte protease inhibitor (SLPI) with improved anti-inflammatory activity against pulmonary infection Source: Lung Science Conference 2015 Year: 2015
Development of secretory leukocyte protease inhibitor (SLPI) variants resistant to degradation by neutrophil elastase Source: International Congress 2014 – New studies into pulmonary proteases and antiproteases Year: 2014
Role of secretory leukocyte protease inhibitor in the development of subclinical emphysema Source: Eur Respir J 2002; 19: 1050-1057 Year: 2002
Decreased levels of secretory leucoprotease inhibitor in the pseudomonas -infected cystic fibrosis lung are due to neutrophil elastase degradation Source: Annual Congress 2009 - Airway inflammation and host defence Year: 2009
Lysosomal cysteine proteases in the lung: role in protein processing and immunoregulation Source: Eur Respir J 2004; 23: 620-628 Year: 2004
Isoenzyme regan – marker enzymatic – in lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 85s Year: 2006
Neutrophil activity assessed using a novel serological marker of human neutrophil elastase degraded calprotectin is elevated in patients with COPD or IPF Source: Virtual Congress 2021 – Advanced in vitro models for drug discovery Year: 2021
Proteinase inhibition regulates the anti-tumor activity of PAI-1 towards lung and prostate cancer cells Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011
Hyaluronidase, hyaluronan synthase, E-cadherin and TGF-beta profile in lung adenocarcinoma subtypes and squamous cell carcinoma of smokers/nonsmokers Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013
Levels of proteinase 3 and neutrophil elastase in plasma, BAL and biopsies in COPD Source: Virtual Congress 2020 – Novel immunopathological mechanisms of lung disease: knowledge from translational studies Year: 2020
Clinical significance of serum cathepsin K level during chemotherapy of lung cancer. Can we use it as a marker of small cell lung cancer? Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008
SerpinB1 in cystic fibrosis airway fluids: quantity, molecular form and mechanism of elastase inhibition Source: Eur Respir J 2011; 37: 1083-1090 Year: 2011
Association of tissue inhibitor of metalloproteinases 2 and 3 polymorphisms with non-small cell Lung cancer Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores Year: 2018
Thrombin activatable fibrinolytic inhibitor in sera from NSCLC patients Source: Eur Respir J 2005; 26: Suppl. 49, 91s Year: 2005
Expression of thrombin-activatable fibrinolysis inhibitor (TAFI) by lung cancer cell lines Source: Eur Respir J 2002; 20: Suppl. 38, 585s Year: 2002
Clinical status and activity of lysosomal carboxypeptidase A and cathepsin D in mixed saliva of cystic fibrosis patients Source: Annual Congress 2008 - Cystic fibrosis: factors affecting lung health Year: 2008